In January 2024, Elon Musk's neurotechnology company Neuralink made headlines by successfully implanting its first brain-computer interface device in a human patient.

By early 2025, at least five people with severe paralysis had received the implant. These individuals — paralyzed from spinal cord injuries or living with ALS — were controlling computers, smartphones, and robotic arms using only their thoughts.

This is not science fiction anymore.

What the Technology Actually Does

Neuralink's current implant, called the N1 or "the Link," is roughly the size of a large coin and sits flush with the skull, invisible under the skin. It contains 1,024 electrode contacts on 64 ultra-thin threads — each thinner than a human hair — that are inserted into the brain's motor cortex by a robotic surgeon with precision no human hand can match. The device charges wirelessly through the skin and transmits data via Bluetooth to external devices.

When a paralyzed patient thinks about moving their hand, neurons in the motor cortex fire. The electrodes detect those electrical signals, software decodes the intent, and the device translates it into a command — moving a cursor on screen, typing a message, controlling a robotic limb. The system learns and improves with use through machine learning algorithms that adapt to each individual's neural patterns.

Beyond Paralysis

The most established application is restoring motor control to people with paralysis — and by June 2025, five patients were actively using Neuralink to control digital and physical devices with thought alone. But the broader BCI field is pushing further. In September 2024, Neuralink received FDA Breakthrough Device Designation for its Blindsight device, aimed at restoring vision. In May 2025, it received the same fast-track designation for a speech restoration device — targeting patients who have lost the ability to speak due to conditions like ALS or cerebrovascular event.

Research institutions including UC Davis and Massachusetts General Hospital have separately demonstrated the ability to decode speech from neural activity. The potential to give a fully locked-in patient — someone with no voluntary movement at all — the ability to communicate is one of the most medically significant possibilities on the horizon.

The Market and the Stakes

The addressable patient population is significant. An estimated 5.4 million people in the US alone live with paralysis that impairs their ability to use computers or communicate. Private market studies compiled by the US Government Accountability Office project the BCI market will expand 10 to 17% annually through 2030. Neuralink has raised $650 million and is valued at approximately $9 billion, with clinical trials expanding to Canada, the UK, Germany, and the UAE.

What Still Needs to Be Resolved

The technology is promising but early. Long-term biocompatibility — whether the implant and surrounding brain tissue remain stable over years or decades — is not yet established. The regulatory pathway from clinical trials to broad approval is still in progress. Ethical questions around data privacy, potential misuse, and equitable access remain unresolved. The vision of a full symbiotic relationship between human intelligence and AI is still far ahead of what the implanted hardware currently enables. What's real today is a small number of people with devastating neurological conditions regaining a degree of independence they'd lost. That's where the genuine significance lies right now.